The prolonged use of bisphosphonates has been associated with osteonecrosis of the jaws. Bisphosphonates are used in the treatment of patients with bone metastases or osteoporosis. The drug reduces bone resorption, promotes osteoblastic activity, inhibits osteoclast recruiting and promotes osteoclast apoptosis. The association between the use of bisphosphonates and extractions may lead to maxillary osteonecrosis. This report describes the clinical case of an oncologic patient treated with zoledronic acid who developed maxillary osteonecrosis after an extraction. The surgical treatment consisted of partial maxillectomy associated with low-level laser therapy. The patient recovered uneventfully and has been receiving dental treatment for oral rehabilitation. Although recurrence of this type of necrotic lesion is frequent, this patient is currently free of any recurrence.

Conflict of interest: None declared.